Quizartinib（Cat No.:I005647）is a potent and selective FLT3 inhibitor used primarily in the treatment of acute myeloid leukemia (AML) with FLT3-ITD mutations. By targeting the FLT3 receptor tyrosine kinase, quizartinib helps inhibit cancer cell proliferation and survival, offering a promising therapeutic option for patients with relapsed or refractory AML. Its selectivity for FLT3 minimizes off-target effects, making it an effective treatment in managing AML. Ongoing research is evaluating its potential in combination therapies to enhance efficacy and improve patient outcomes in hematologic malignancies.
| Catalog Number | I005647 |
| CAS Number | 950769-58-1 |
| Synonyms | 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea |
| Molecular Formula | C₂₉H₃₂N₆O₄S |
| Purity | ≥95% |
| Target | FLT3 |
| Solubility | DMSO: ≥ 33 mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 1.1 nM/4.2 nM( Flt3 ITD/WT) |
| IUPAC Name | 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea |
| InChI | InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36) |
| InChIKey | CVWXJKQAOSCOAB-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3 |
| Reference | [1]. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992. |
